Skip to main content
2023 Guide to Patient Support Services

Gilead Sciences

2023 PSS Guide

Gilead Sciences Support Services

Trodelvy Access Support
Zydelig AccessConnect

Gilead Sciences offers the Trodelvy Access Support and the Zydelig AccessConnect programs for patients who are prescribed Trodelvy or Zydelig (Table).

Trodelvy Access Support

Trodelvy Savings Program

The Trodelvy Savings Program provides savings on out-of-pocket expenses for Trodelvy for commercially or privately insured patients. Patients pay $0 out of pocket for Trodelvy, which includes copay and coinsurance up to $25,000 annually. Terms and conditions apply.

  • The program assists with cost of Trodelvy only; patient is responsible for costs of office visits and treatment expenses
  • This program does not support any claims covered, paid, or reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs.

For additional information about any support issues, contact Trodelvy Access Support at 844-876-3358, option 4.

Gilead Patient Assistance Program

Patients who are uninsured or underinsured may be eligible to obtain access to Trodelvy at no cost through the Gilead Patient Assistance Program. To determine eligibility, patients must send a completed Enrollment Form via mail or fax. Patients must be legal residents of the United States and meet income requirements and certain additional eligibility criteria.

Third-Party Assistance Referrals

Trodelvy Access Support Case Managers can provide patients who are unable to afford their medication (including those with Medicare, Medicaid, or other government-sponsored insurance) with information about independent third-party organizations that may be able to help with the cost of treatment. Call 844-876-3358, option 4 for more details.

Zydelig AccessConnect

Copay Coupon Card

Qualified patients with commercial insurance and a copay above $5 may qualify for copay assistance through the Zydelig AccessConnect Copay Coupon Card program. This program will cover out-of-pocket costs for Zydelig after the first $5 per prescription refill up to a maximum of 25% of the catalog price annually. To qualify, patients must:

  • Have a valid prescription for Zydelig
  • Reside in the United States, Puerto Rico, or US territories
  • Be at least 18 years old
  • Not be enrolled in any federal- or state-funded health insurance programs (eg, Medicaid, Medicare, or Medigap).

Patient Assistance Program

Uninsured patients may be eligible to receive Zydelig free of charge through the Zydelig AccessConnect Patient Assistance Program. To qualify, patients must:

  • Enroll in Zydelig AccessConnect
  • Not have prescription coverage for the requested medication
  • Reside in the United States
  • Receive care from a US physician
  • Meet certain income criteria.

Zydelig QuickStart Program

The Zydelig QuickStart Program offers a free 30-day supply of Zydelig for eligible patients experiencing an insurance delay of more than 5 business days. There is no purchase obligation for participation in the QuickStart Program, but certain restrictions may apply.

Government Insurance Support

Zydelig AccessConnect can refer patients who have government insurance but still need financial aid to alternative financial support resources. Independent copay foundations may be able to help with paying for Zydelig copays, coinsurance, and other related expenses. These independent nonprofit foundations have their own eligibility criteria and application processes and are not affiliated with or controlled by Gilead.

TABLE Gilead Sciences Oncology Drugs

Patient support programs

Trodelvy (sacituzumab govitecan-hziy)
Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior systemic therapies, at least 1 of them for metastatic disease; adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor
Patient support programs

Zydelig (idelalisib)
Treatment of patients with relapsed chronic lymphocytic leukemia, in combination with rituximab, for whom rituximab alone would be considered appropriate therapy due to other comorbidities
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"